Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 8/20 | 0.49 |
| ▸ | CDC25B | P30305 | 8/20 | 0.49 |
| ▸ | SSTR1 | P30872 | 6/20 | 0.49 |
| ▸ | SSTR2 | P30874 | 6/20 | 0.49 |
| ▸ | SSTR4 | P31391 | 6/20 | 0.49 |
| ▸ | SSTR3 | P32745 | 6/20 | 0.49 |
| ▸ | SSTR5 | P35346 | 6/20 | 0.49 |
| ▸ | PTPN2 | P17706 | 4/20 | 0.46 |
| ▸ | PTPN6 | P29350 | 4/20 | 0.46 |
| ▸ | PTPN11 | Q06124 | 4/20 | 0.46 |
| ▸ | NT5E | P21589 | 1/20 | 0.44 |
| ▸ | TACR1 | P25103 | 2/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7588437 | 0.87 | PTPN1 (0.50) | PTPN1CDC25BSSTR1SSTR2SSTR4 | |
| SCHEMBL14519962 | 0.79 | PTPN1 (0.52) | PTPN1CDC25BSSTR1SSTR2SSTR4 | |
| SCHEMBL8577146 | 0.78 | SSTR4 (0.63) | PTPN1CDC25BSSTR1SSTR2SSTR4 | |
| SCHEMBL6235796 | 0.78 | SSTR4 (0.69) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL6889266 | 0.78 | SSTR1 (0.56) | PTPN1CDC25BSSTR1SSTR2SSTR4 | |
| SCHEMBL7594539 | 0.78 | SSTR1 (0.56) | PTPN1CDC25BSSTR1SSTR2SSTR4 | |
| SCHEMBL12380725 | 0.78 | SSTR1 (0.56) | PTPN1CDC25BSSTR1SSTR2SSTR4 | |
| SCHEMBL5702598 | 0.78 | SSTR4 (0.69) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL14519966 | 0.78 | SSTR1 (0.56) | PTPN1CDC25BSSTR1SSTR2SSTR4 | |
| SCHEMBL2292522 | 0.78 | SSTR1 (0.56) | PTPN1CDC25BSSTR1SSTR2SSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020002140-A1 | Novel bisphosphonates and uses thereof | STRAKAN LIMITED (BM) | 2002-01-03 | — | — | US | disclosed |
| WO-2001051497-A1 | NOVEL BISPHOSPHONATES AND USES THEREOF | STRAKAN LIMITED (BM) | 2001-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020002140-A1 | Novel bisphosphonates and uses thereof | SOST, PHPT1, BPGM | PTPN1 581/4885CDC25B 1566/4885SSTR1 2766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.